Zantac® Cancer Leads
Velawcity is a legal advertising network that helps mass tort attorneys find claimants who are suffering from cancer after being prescribed Zantac®. The Zantac® leads we send to law firms across the nation always meet the intake criteria given to us by the law firm. If your law firm is looking to find more claimants with cancer caused by Zantac, contact Velawcity to get started today.
Are you searching for Mass Tort Leads that aren’t Zantac®? If your law firm doesn’t need Zantac® cancer leads, we can discuss a different campaign and start sending qualified claimants to your law firm. Fill out the form or give us a call to discuss your upcoming campaign.
Ready For Zantac® Leads?
Start Your Zantac® Campaign Today
Velawcity provides pre-screening intake services for law firms nationwide. Our call center is located in the United States.
We remain compliant with CCPA, TCPA, CAN-SPAM and ABA Advertising and Ethical Guidelines.
Zantac Lawsuit
On September 13, 2019 the Food and Drug Administration issued a warning that the heartburn medicine Zantac® (Ranitidine) contains the cancer-causing chemical Nitrosodimethylamine (NDMA). The FDA issued a warning after a pharmacy in Connecticut discovered elevated levels of NDMA while testing Zantac. It has been reported that the levels of cancer-causing NDMA are anywhere from 3,000 to 26,000 times higher than the legally allowable limit set by the FDA. Zantac® and its generic versions were pulled from shelves of Walmart, Rite Aid, CVS and Walgreens stores after the FDA announced that it had detected the cancer-causing chemical in samples of the drug.
Based upon testing by a popular independent laboratory and a petition filed with the FDA, there are medical claims that Zantac® causes high levels of NDMA exposure in users. Recent studies have confirmed that the unstable particles of the medication break down in the digestive tract to create harmful levels of NDMA. Based on these claims, significant NDMA exposure could result from taking brand name or generic Zantac® products, regardless of the manufacturer.
Similar types of NDMA exposure have been linked to various cancers, including:
- Liver cancer
- Kidney cancer
- Lung cancer
- Intestinal cancer
- Stomach cancer
- Pancreatic cancer
- Bladder Cancer
- Colon cancer
- Ovarian cancer
- Esophageal cancer
- Testicular Cancer
- And more
Contact Velawcity Today To Start Your Zantac® Campaign
What Law Firms Have To Say
"We have put our trust in Velawcity for many different claims. I have never had to worry about their performance. They have always been very transparent and available to communicate regarding our campaigns. I feel like Velawcity is an extension of our core business and trust them implicitly."
“The entire Velawcity team is terrific to work with. They use cutting edge technology and a proprietary approach that gives us a huge competitive advantage in acquiring qualified clients for our Mass Tort practice. They exemplify integrity, have an incredible work ethic and I highly recommend them.”
"Velawcity has earned our trust. They provide quality leads and deliver on their promise. Most importantly, the entire team is transparent and easy to work with. Thank you to Brian and Shane for being there every step of the way and making our campaigns as smooth and efficient as possible."
"The team at Velawcity always puts their clients first. They have provided quality leads to us quicker than any other lead generation company out there. They are fast, responsive, and take the necessary time to understand the cases they are advertising for. We would not have been able to scale the way we have without the team at Velawcity."
"The team at Velawcity delivers excellent results. They strike the right balance of delivering quality leads at the most competitive price. Most importantly, as working with any marketing team, they are trustworthy and straight shooters."
"Great company! Fast and efficient. They deliver as promised. Tighe and Phil are really great to work with."
References:
https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134800/